ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Tucatinib (Tukysa)

HER2-positive breast cancer Tukysa is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable or metastatic HER2-positive breast cancer following first-line chemotherapy.

CHMP opinion 15 Oct 2026 · Pfizer Europe MA EEIG

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.